Blog
RSS FeedPosted by Michael Wonder on 29 Nov 2020
PBS support for Australians living with leukaemia
28 November 2020 - Patients living with one of Australia’s most common forms of leukaemia are set to benefit from expanded ...
Posted by Michael Wonder on 13 Nov 2020
Public Summary Documents - PBAC July 2020 meeting
13 November 2020 - The Public Summary Documents (first time rejections and deferrals) from the July 2020 PBAC meeting are now ...
Posted by Michael Wonder on 10 Nov 2020
Patients in other countries are getting access to breakthrough cancer drugs faster than Aussies
11 November 2020 - Old news and hardly an exclusive. ...
Posted by Michael Wonder on 10 Nov 2020
Mirum Pharmaceuticals broadens Expanded Access Program for maralixibat in Alagille syndrome to Europe and Australia
5 November 2020 - Maralixibat Expanded Access Program now available for patients with pruritus associated with Alagille syndrome in Australia and ...
Posted by Michael Wonder on 09 Nov 2020
Post-market review of medicines for smoking cessation – targeted stakeholder forum
9 November 2020 - A Stakeholder Forum will be held via webinar for the post-market review of medicines for smoking cessation ...
Posted by Michael Wonder on 03 Nov 2020
Fury as ‘life-changing’ eczema drug fails to make PBS
3 November 2020 - A “life-changing” drug was supposed to be approved for the Pharmaceutical Benefits Scheme months ago, but eczema ...
Posted by Michael Wonder on 03 Nov 2020
Department publishes revised agenda for November 2020 PBAC meeting
3 November 2020 - One late change ahead of tomorrow's meeting. ...
Posted by Michael Wonder on 02 Nov 2020
PBAC recommends price increase for paracetamol
30 October 2020 - A fascinating insight from the first round of Public Summary Documents from the July 2020 PBAC ...
Posted by Michael Wonder on 01 Nov 2020
Schedule of Pharmaceutical Benefits - 1 November 2020
1 November 2020 - The November 2020 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Oct 2020
Public Summary Documents - PBAC July 2020
30 October 2020 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2020 PBAC ...
Posted by Michael Wonder on 25 Oct 2020
New medicines for Australians with multiple sclerosis, lymphoma, carcinoma and reproductive cancers
25 October 2020 - Australians living with multiple sclerosis, and various forms of cancer will benefit from an Australian Government investment ...
Posted by Michael Wonder on 24 Oct 2020
MS patients granted lifeline with ‘effective’ drug listed on PBS
24 October 2020 - Patients who develop the second progressive stage of multiple sclerosis will only have to pay $41 for ...
Posted by Michael Wonder on 21 Oct 2020
Access to the latest and most effective diabetes drugs depends on where you live and what you earn
21 October 2020 - Access to the latest and most effective drugs for Australians with diabetes can depend on where ...
Posted by Michael Wonder on 21 Oct 2020
‘It really seems cruel’: drug giant’s brutal blow to Australian breast cancer patients
21 October 2020 - Terminally ill breast cancer patients will have to pay $1,600 a month for a lifesaving treatment, after ...
Posted by Michael Wonder on 18 Oct 2020
PBAC recommends Zeposia for patients with relapsing-remitting multiple sclerosis
16 October 2020 - Did Celgene really request its use for the treatment of non-premenopausal patients with hormone receptor positive, ...